Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits

The current interest in recombinant factor VIII (rFVIII) products stems from the fact that they offer a technological solution to prolonging the half-life of and reducing the risk of formation of alloantibodies (inhibitors) against FVIII in treated patients with hemophilia A (HA). The Italian health...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Med (Lausanne)
Main Authors: Schiavoni, Mario, Napolitano, Mariasanta, Giuffrida, Gaetano, Coluccia, Antonella, Siragusa, Sergio, Calafiore, Valeria, Lassandro, Giuseppe, Giordano, Paola
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2019
Assuntos:
Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6901793/
https://ncbi.nlm.nih.gov/pubmed/31850352
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmed.2019.00261
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados